{"id":675244,"date":"2025-06-15T10:55:13","date_gmt":"2025-06-15T07:55:13","guid":{"rendered":"https:\/\/en.buradabiliyorum.com\/blocking-cd200r1-protein-offers-new-strategy-for-treatment-resistant-blood-cancers-2\/"},"modified":"2025-06-15T10:55:13","modified_gmt":"2025-06-15T07:55:13","slug":"blocking-cd200r1-protein-offers-new-strategy-for-treatment-resistant-blood-cancers-2","status":"publish","type":"post","link":"https:\/\/buradabiliyorum.com\/en\/blocking-cd200r1-protein-offers-new-strategy-for-treatment-resistant-blood-cancers-2\/","title":{"rendered":"Blocking CD200R1 protein offers new strategy for treatment-resistant blood cancers"},"content":{"rendered":"
\n
\n
\n
\n \"Immunotherapy:
\n CD200R1, a CD11b-interacting protein, inhibits phagocytosis. Credit: Nature Communications<\/i> (2025). DOI: 10.1038\/s41467-025-60456-3
\n <\/figcaption><\/figure>\n<\/p><\/div>\n<\/div>\n

Immunotherapy has revolutionized cancer treatment by mobilizing the immune system to attack tumor cells. Major advances, such as immune checkpoint inhibitors (notably against the PD-1 protein), have produced impressive results against certain types of cancer, including melanoma and kidney cancer.<\/p>\n

These treatments “take the brakes off” the immune system, increasing its ability to detect and destroy cancer cells. However, despite their effectiveness, these treatments do not work for all patients or all types of cancer. This realization has prompted researchers around the world to search for new therapeutic targets.<\/p>\n

Now comes work carried out in the laboratory of Universit\u00e9 de Montr\u00e9al medical professor Dr. Andr\u00e9 Veillette, director of the molecular oncology research unit of the Montreal Clinical Research Institute (IRCM), in collaboration with scientists from several countries, marks a breakthrough in the fight against treatment-refractory cancers.<\/p>\n

Led by Jiaxin Li, a doctoral student in Veillette’s lab, the researchers have discovered a new molecule of interest called CD200R1. The finding is detailed in a study published<\/a> in the journal Nature Communications<\/i>.<\/p>\n

CD200R1 is a protein present on the surface of certain immune cells called macrophages, which play a key role in detecting and destroying abnormal cells. The new research shows that blocking CD200R1 with specific antibodies activates macrophages, helping to eliminate blood cancers such as leukemia and lymphoma in preclinical mouse models.<\/p>\n

These results pave the way for a new therapeutic app<\/a>roach for cancers that are resistant to current treatments, the scientists believe. The next step for Veillette and his team is to develop collaborations aimed at proving that this strategy can also work in humans, which could transform treatment options for many patients.<\/p>\n

\n

More information:<\/strong>
\n Jiaxin Li et al, CD200R1-CD200 checkpoint inhibits phagocytosis differently from SIRP\u03b1-CD47 to suppress tumor growth, Nature Communications<\/i> (2025). DOI: 10.1038\/s41467-025-60456-3<\/a><\/p>\n<\/p><\/div>\n

\n\t\t\t\t\t\t\t\t\t\t\t\tProvided by
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tUniversity of Montreal
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/svg>
\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/a><\/p><\/div>\n

<\/p>\n

\n

\n Citation<\/strong>:
\n Blocking CD200R1 protein offers new strategy for treatment-resistant blood cancers (2025, June 13)
\n retrieved 15 June 2025
\n from https:\/\/medicalxpress.com\/news<\/a>\/2025-06-blocking-cd200r1-protein-strategy-treatment.html\n <\/p>\n

\n This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
\n part may be reproduced without the written permission. The content is provided for information purposes only.\n <\/p>\n<\/p><\/div>\n<\/p><\/div>\n